RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO – March 28, 2012 – Quintiles and Archimedes Inc. today announced an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies. Through this partnership, Quintiles will incorporate Archimedes’ industry-leading healthcare modeling technology, the ARCHeS Innovator, and expertise into its existing solutions that span the product lifecycle.
“ARCHeS Innovator is a tremendous tool for capturing predictive simulations from real-world research, which is vital to helping biopharma improve efficiency and productivity in the New Health,” said Rick Sax, Global Head of Integrated Clinical Services for Quintiles. “Turning data into insights will allow customers to make faster, better decisions across the product lifecycle and increase their probability of success.”
Quintiles will promote and provide access to ARCHeS Innovator, a Software as a Service (SAAS) solution that gives users direct access to the Archimedes Model. The Archimedes Model is a full-scale computer simulation model of human physiology, diseases, behaviors, interventions and healthcare systems. Through advanced methods of mathematics, computing and data systems, the Model enables users to run clinically realistic virtual trials that drive better decisions in health and economic outcomes research, comparative effectiveness research, clinical trial design and portfolio management.
Mika Newton, Vice President, ARCHeS & Consulting Business Leader for Archimedes, said: “Biopharma companies are under enormous pressure to maximize the efficiency and strategic positioning of products they are developing and marketing. This partnership between Archimedes and Quintiles makes advanced simulation modeling and premier medical evidence accessible and fully integrated into customers’ clinical research and commercial activities.”
Michael Ackermann, Senior Vice President in the Commercial Group at Quintiles, said: “Being able to forecast potential outcomes to interventions brings tremendous value for our biopharma customers, who need to increase productivity, shorten timelines and manage risk. Through the simulation and modeling capabilities of Archimedes, we can provide estimates on the impact of interventions, experimental protocols and guidelines on long-term outcomes. This has applications in clinical trial design, product development, commercialization and patient engagement to help our customers increase the probability of their success.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com/ for more information and www.quintiles.com/news for additional company news.
Archimedes Inc. is a healthcare modeling organization. Its core technology – the Archimedes Model – is a clinically realistic, mathematical model of human physiology, diseases, interventions and healthcare systems. The Model is continually validated by comparing the results of simulated trials to the results of real clinical trials and cohort studies. Through innovations such as ARCHeS and IndiGO, Archimedes helps people understand the implications of their decisions and for the last 15 years has been relied upon to answer complex, real world questions for health plans, health systems, medical groups, pharmaceutical companies, researchers, and other organizations in the United States and Europe. Archimedes, a Kaiser Permanente Innovation, is based in San Francisco, California.